Effect of smoking status on the efficacy of the SMART regimen in high risk asthma

Background and objective: The optimal management of people with asthma with a significant smoking history is uncertain. The aim of this study was to determine whether the efficacy/safety profile of single combination inhaled corticosteroid (ICS)/long acting beta-agonist (LABA) inhaler maintenance an...

Full description

Bibliographic Details
Main Authors: Pilcher, Janine, Patel, Mitesh, Reddel, Helen K., Pritchard, Alison, Black, Peter, Shaw, Dominick E., Holt, Shaun, Weatherall, Mark, Beasley, Richard
Format: Article
Published: Wiley 2016
Subjects:
Online Access:https://eprints.nottingham.ac.uk/34004/
_version_ 1848794753805582336
author Pilcher, Janine
Patel, Mitesh
Reddel, Helen K.
Pritchard, Alison
Black, Peter
Shaw, Dominick E.
Holt, Shaun
Weatherall, Mark
Beasley, Richard
author_facet Pilcher, Janine
Patel, Mitesh
Reddel, Helen K.
Pritchard, Alison
Black, Peter
Shaw, Dominick E.
Holt, Shaun
Weatherall, Mark
Beasley, Richard
author_sort Pilcher, Janine
building Nottingham Research Data Repository
collection Online Access
description Background and objective: The optimal management of people with asthma with a significant smoking history is uncertain. The aim of this study was to determine whether the efficacy/safety profile of single combination inhaled corticosteroid (ICS)/long acting beta-agonist (LABA) inhaler maintenance and reliever therapy is influenced by smoking status. Methods: We undertook secondary analyses from an open-label 24-week randomized study of 303 high risk adult asthma patients randomized to budesonide/formoterol 200/6-µg-metred dose inhaler for maintenance (two actuations twice daily) and either budesonide/formoterol 200/6-µg-metred dose inhaler one actuation (‘single ICS/LABA maintenance and reliever therapy (SMART)’ regimen) or salbutamol 100 µg 1–2 actuations for symptom relief (‘Standard’ regimen). Smoking status was classified in to three groups, as ‘current’, ‘ex’ or ‘never’, and a smoking/treatment interaction term tested for each outcome variable. The primary outcome variable was number of participants with at least one severe exacerbation. Results: There were 59 current, 97 ex and 147 never smokers included in the analyses. The smoking status/treatment interaction term was not statistically significant for any of the outcome measures. With adjustment for smoking status, the number of participants with severe exacerbations was lower with the SMART regimen (OR 0.45, 95% CI: 0.26–0.77, P = 0.004; P value for interaction between smoking status and treatment 0.29). Conclusion: We conclude that the favourable safety/efficacy profile of the SMART regimen applies to patients with high risk asthma, irrespective of smoking status.
first_indexed 2025-11-14T19:21:12Z
format Article
id nottingham-34004
institution University of Nottingham Malaysia Campus
institution_category Local University
last_indexed 2025-11-14T19:21:12Z
publishDate 2016
publisher Wiley
recordtype eprints
repository_type Digital Repository
spelling nottingham-340042020-05-04T17:36:20Z https://eprints.nottingham.ac.uk/34004/ Effect of smoking status on the efficacy of the SMART regimen in high risk asthma Pilcher, Janine Patel, Mitesh Reddel, Helen K. Pritchard, Alison Black, Peter Shaw, Dominick E. Holt, Shaun Weatherall, Mark Beasley, Richard Background and objective: The optimal management of people with asthma with a significant smoking history is uncertain. The aim of this study was to determine whether the efficacy/safety profile of single combination inhaled corticosteroid (ICS)/long acting beta-agonist (LABA) inhaler maintenance and reliever therapy is influenced by smoking status. Methods: We undertook secondary analyses from an open-label 24-week randomized study of 303 high risk adult asthma patients randomized to budesonide/formoterol 200/6-µg-metred dose inhaler for maintenance (two actuations twice daily) and either budesonide/formoterol 200/6-µg-metred dose inhaler one actuation (‘single ICS/LABA maintenance and reliever therapy (SMART)’ regimen) or salbutamol 100 µg 1–2 actuations for symptom relief (‘Standard’ regimen). Smoking status was classified in to three groups, as ‘current’, ‘ex’ or ‘never’, and a smoking/treatment interaction term tested for each outcome variable. The primary outcome variable was number of participants with at least one severe exacerbation. Results: There were 59 current, 97 ex and 147 never smokers included in the analyses. The smoking status/treatment interaction term was not statistically significant for any of the outcome measures. With adjustment for smoking status, the number of participants with severe exacerbations was lower with the SMART regimen (OR 0.45, 95% CI: 0.26–0.77, P = 0.004; P value for interaction between smoking status and treatment 0.29). Conclusion: We conclude that the favourable safety/efficacy profile of the SMART regimen applies to patients with high risk asthma, irrespective of smoking status. Wiley 2016-02-21 Article PeerReviewed Pilcher, Janine, Patel, Mitesh, Reddel, Helen K., Pritchard, Alison, Black, Peter, Shaw, Dominick E., Holt, Shaun, Weatherall, Mark and Beasley, Richard (2016) Effect of smoking status on the efficacy of the SMART regimen in high risk asthma. Respirology, 21 (5). pp. 858-866. ISSN 1440-1843 Adult asthma medication adherence randomized controlled trial smoking http://onlinelibrary.wiley.com/doi/10.1111/resp.12740/abstract;jsessionid=26F767E582D391F090EE903D072DB882.f02t04 doi:10.1111/resp.12740 doi:10.1111/resp.12740
spellingShingle Adult
asthma
medication adherence
randomized controlled trial
smoking
Pilcher, Janine
Patel, Mitesh
Reddel, Helen K.
Pritchard, Alison
Black, Peter
Shaw, Dominick E.
Holt, Shaun
Weatherall, Mark
Beasley, Richard
Effect of smoking status on the efficacy of the SMART regimen in high risk asthma
title Effect of smoking status on the efficacy of the SMART regimen in high risk asthma
title_full Effect of smoking status on the efficacy of the SMART regimen in high risk asthma
title_fullStr Effect of smoking status on the efficacy of the SMART regimen in high risk asthma
title_full_unstemmed Effect of smoking status on the efficacy of the SMART regimen in high risk asthma
title_short Effect of smoking status on the efficacy of the SMART regimen in high risk asthma
title_sort effect of smoking status on the efficacy of the smart regimen in high risk asthma
topic Adult
asthma
medication adherence
randomized controlled trial
smoking
url https://eprints.nottingham.ac.uk/34004/
https://eprints.nottingham.ac.uk/34004/
https://eprints.nottingham.ac.uk/34004/